Salvioli G, Carati L, Lugli R
Department of Special Medical Pathology, University of Modena, Italy.
J Int Med Res. 1990 Jul-Aug;18(4):289-97. doi: 10.1177/030006059001800405.
In a double-blind, crossover study, 10 cirrhotic patients (Child B rating) with steatorrhoea (daily output of faecal fat greater than 8 g) and dyspepsia were placed on a controlled diet for 14 days. Patients then received 150 mg ursodeoxycholic acid (UDCA) or placebo twice daily for 14 days. Faecal fat excretion was reduced from 14.7 to 10.6 g/day by UDCA and dyspepsia symptom scores were also reduced. Serum aspartate aminotransferase concentrations declined significantly (P less than 0.02) following UDCA treatment, whereas serum bile acid levels increased from 35 to 40.5 microM and the percentage of UDCA increased to 22%. It is concluded that UDCA may be useful for many of the symptoms present in patients with liver cirrhosis.
在一项双盲交叉研究中，10名患有脂肪泻（每日粪便脂肪排出量大于8克）和消化不良的肝硬化患者（Child B级）接受了14天的控制饮食。然后，患者每天两次接受150毫克熊去氧胆酸（UDCA）或安慰剂治疗，持续14天。UDCA使粪便脂肪排泄量从每天14.7克降至10.6克，消化不良症状评分也有所降低。UDCA治疗后，血清天冬氨酸转氨酶浓度显著下降（P小于0.02），而血清胆汁酸水平从35微摩尔升至40.5微摩尔，UDCA的百分比增至22%。结论是，UDCA可能对肝硬化患者出现的许多症状有用。
